Danielle C. Cath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Danielle C. Cath has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Richard Bruggeman
University of Groningen
2 shared publications - Amrit Sandhu
Department of Epidemiology, University Medical Centre Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
1 shared publication - Anouk Den Braber
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam Netherlands
1 shared publication - Arne J. Risselada
Department of Clinical Pharmacy, Wilhelmina Hospital, Assen, The Netherlands
1 shared publication - Behrooz Z. Alizadeh
Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication - Bennard Doornbos
Department of Specialized Training, Psychiatric Hospital MHS Drenthe, Outpatient Clinics, Assen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 8 September 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 46 (1) , 44-54
Gender Differences in Psychotropic Medication Use
Purpose/Background: Previous studies among psychiatric patients have shown differences between men and women in psychotropic medication prescription patterns. The factors underlying these differences are still poorly understood. This exploratory study aimed to investigate a range of clinical and demographic factors in their contributions to explaining these gender differences. Methods/Procedures: In 2476 outpatients with a mental disorder (mean age 46.1 year, 58.2% women) enrolled in pharmacotherapy monitoring program, regression analyses were used to investigate the associations of gender with use of any psychotropic (yes/no), use of each separate psychotropic type (yes/no), number (0 to 4) and dosage of each used psychotropic. Next, clinical and demographic effect modifiers and explanatory/confounding factors of these associations were identified. Findings/Results: Frequencies of general psychotropic use, antidepressant use, anxiolytic use, as well as polypharmacy were significantly higher in women than in men across all ages (premenopausal, perimenopausal, and postmenopausal), with equal dosing of psychotropics, except for higher doses of mood stabilizers in men. Longer illness duration and having a partner were effect modifiers of the gender effect, while higher frequencies of an affective/anxiety diagnosis, higher somatic complaints and symptomatic distress, more previous mental health service (MHS) visits and no current occupation were explanatory factors. Implications/Conclusions: Psychotropic use and psychotropic polypharmacy were more common in women than in men. Women on psychotropic medications were more often diagnosed with affective/anxiety diagnoses, experienced more symptomatic distress and somatic complaints, and visited more healthcare services than men, reaffirming findings from previous studies. Future longitudinal studies should investigate in further detail whether these outcomes are cause or consequence of gender differences in psychotropic medication use.
- 8 September 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 46 (1) , 44-54
Open AccessGender Differences in Psychotropic Medication Use
Purpose/Background: Previous studies among psychiatric patients have shown differences between men and women in psychotropic medication prescription patterns. The factors underlying these differences are still poorly understood. This exploratory study aimed to investigate a range of clinical and demographic factors in their contributions to explaining these gender differences. Methods/Procedures: In 2476 outpatients with a mental disorder (mean age 46.1 year, 58.2% women) enrolled in pharmacotherapy monitoring program, regression analyses were used to investigate the associations of gender with use of any psychotropic (yes/no), use of each separate psychotropic type (yes/no), number (0 to 4) and dosage of each used psychotropic. Next, clinical and demographic effect modifiers and explanatory/confounding factors of these associations were identified. Findings/Results: Frequencies of general psychotropic use, antidepressant use, anxiolytic use, as well as polypharmacy were significantly higher in women than in men across all ages (premenopausal, perimenopausal, and postmenopausal), with equal dosing of psychotropics, except for higher doses of mood stabilizers in men. Longer illness duration and having a partner were effect modifiers of the gender effect, while higher frequencies of an affective/anxiety diagnosis, higher somatic complaints and symptomatic distress, more previous mental health service (MHS) visits and no current occupation were explanatory factors. Implications/Conclusions: Psychotropic use and psychotropic polypharmacy were more common in women than in men. Women on psychotropic medications were more often diagnosed with affective/anxiety diagnoses, experienced more symptomatic distress and somatic complaints, and visited more healthcare services than men, reaffirming findings from previous studies. Future longitudinal studies should investigate in further detail whether these outcomes are cause or consequence of gender differences in psychotropic medication use.
- Open Access
- 29 January 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 9 (3)
Lifestyle interventions for depression in primary care: a qualitative study
Background In individuals with depression a vicious circle tends to occur in which depressive symptoms cause an unhealthy lifestyle, which reversibly causes an increase in depressive symptoms; both of which are associated with a decreased life expectancy. A potential way to break this circle entails a multicomponent lifestyle intervention (MLI). Aim Exploring the barriers and facilitators for an MLI in patients with depressive symptoms from the perspective of general practitioners (GP), chronic disease practice nurses (CD-PN), mental health nurses (MHN), lifestyle coaches (LC) and patients (PT). Design & setting Qualitative study using semi-structured interviews in Dutch primary care. Methods We interviewed 5 GPs, 6 MHNs, 5 CD-PNs, 5 LCs and 7 PTs. Focus was on possible barriers and facilitators for an MLI. Data were analyzed using thematic analysis. A focus group was used as a member check. Results Five themes were identified: ‘expectations of effectiveness, ‘motivation’, ‘stigma’, ‘logistics and organization’ and ‘communication by professionals’. Conclusion Ideas on effectiveness were crucial and could be either a facilitator or a barrier for a DT-MLI. Professionals often had high expectations, based on work experience, making this a facilitator. Other facilitators are motivating participants, good logistics and good communication by professionals, thus destigmatizing depression. Patients considered being motivated by the program as a reason for participating, as they did not expect a DT-MLI would give them new information. Support from others was considered a motivator to participate.
- 29 January 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 9 (3)
Open AccessLifestyle interventions for depression in primary care: a qualitative study
Background In individuals with depression a vicious circle tends to occur in which depressive symptoms cause an unhealthy lifestyle, which reversibly causes an increase in depressive symptoms; both of which are associated with a decreased life expectancy. A potential way to break this circle entails a multicomponent lifestyle intervention (MLI). Aim Exploring the barriers and facilitators for an MLI in patients with depressive symptoms from the perspective of general practitioners (GP), chronic disease practice nurses (CD-PN), mental health nurses (MHN), lifestyle coaches (LC) and patients (PT). Design & setting Qualitative study using semi-structured interviews in Dutch primary care. Methods We interviewed 5 GPs, 6 MHNs, 5 CD-PNs, 5 LCs and 7 PTs. Focus was on possible barriers and facilitators for an MLI. Data were analyzed using thematic analysis. A focus group was used as a member check. Results Five themes were identified: ‘expectations of effectiveness, ‘motivation’, ‘stigma’, ‘logistics and organization’ and ‘communication by professionals’. Conclusion Ideas on effectiveness were crucial and could be either a facilitator or a barrier for a DT-MLI. Professionals often had high expectations, based on work experience, making this a facilitator. Other facilitators are motivating participants, good logistics and good communication by professionals, thus destigmatizing depression. Patients considered being motivated by the program as a reason for participating, as they did not expect a DT-MLI would give them new information. Support from others was considered a motivator to participate.
- Open Access
- 27 May 2024
- Published by Springer Nature in BMC Psychiatry
- Vol. 24 (1) , 1-14
Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study
Background: Tailoring antidepressant drugs (AD) to patients’ genetic drug-metabolism profile is promising. However, literature regarding associations of ADs’ treatment effect and/or side effects with drug metabolizing genes CYP2D6 and CYP2C19 has yielded inconsistent results. Therefore, our aim was to longitudinally investigate associations between CYP2D6 (poor, intermediate, and normal) and CYP2C19 (poor, intermediate, normal, and ultrarapid) metabolizer-status, and switching/discontinuing of ADs. Next, we investigated whether the number of perceived side effects differed between metabolizer statuses. Methods: Data came from the multi-site naturalistic longitudinal cohort Netherlands Study of Depression and Anxiety (NESDA). We selected depression- and/or anxiety patients, who used AD at some point in the course of the 9 years follow-up period (n = 928). Medication use was followed to assess patterns of AD switching/discontinuation over time. CYP2D6 and CYP2C19 alleles were derived using genome-wide data of the NESDA samples and haplotype data from the PharmGKB database. Logistic regression analyses were conducted to investigate the association of metabolizer status with switching/discontinuing ADs. Mann–Whitney U-tests were conducted to compare the number of patient-perceived side effects between metabolizer statuses. Results: No significant associations were observed of CYP metabolizer status with switching/discontinuing ADs, nor with the number of perceived side effects. Conclusions: We found no evidence for associations between CYP metabolizer statuses and switching/discontinuing AD, nor with side effects of ADs, suggesting that metabolizer status only plays a limited role in switching/discontinuing ADs. Additional studies with larger numbers of PM and UM patients are needed to further determine the potential added value of pharmacogenetics to guide pharmacotherapy.
- 27 May 2024
- Published by Springer Nature in BMC Psychiatry
- Vol. 24 (1) , 1-14
Open AccessAssociation of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study
Background: Tailoring antidepressant drugs (AD) to patients’ genetic drug-metabolism profile is promising. However, literature regarding associations of ADs’ treatment effect and/or side effects with drug metabolizing genes CYP2D6 and CYP2C19 has yielded inconsistent results. Therefore, our aim was to longitudinally investigate associations between CYP2D6 (poor, intermediate, and normal) and CYP2C19 (poor, intermediate, normal, and ultrarapid) metabolizer-status, and switching/discontinuing of ADs. Next, we investigated whether the number of perceived side effects differed between metabolizer statuses. Methods: Data came from the multi-site naturalistic longitudinal cohort Netherlands Study of Depression and Anxiety (NESDA). We selected depression- and/or anxiety patients, who used AD at some point in the course of the 9 years follow-up period (n = 928). Medication use was followed to assess patterns of AD switching/discontinuation over time. CYP2D6 and CYP2C19 alleles were derived using genome-wide data of the NESDA samples and haplotype data from the PharmGKB database. Logistic regression analyses were conducted to investigate the association of metabolizer status with switching/discontinuing ADs. Mann–Whitney U-tests were conducted to compare the number of patient-perceived side effects between metabolizer statuses. Results: No significant associations were observed of CYP metabolizer status with switching/discontinuing ADs, nor with the number of perceived side effects. Conclusions: We found no evidence for associations between CYP metabolizer statuses and switching/discontinuing AD, nor with side effects of ADs, suggesting that metabolizer status only plays a limited role in switching/discontinuing ADs. Additional studies with larger numbers of PM and UM patients are needed to further determine the potential added value of pharmacogenetics to guide pharmacotherapy.
- Open Access
- 4 September 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (9) , 1354
Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
Schizophrenia spectrum disorders (SSD) are complex mental disorders, and while treatment with antipsychotics is important, many patients do not respond or develop serious side effects. Genetic variation has been shown to play a considerable role in determining an individual’s response to antipsychotic medication. However, previous pharmacogenetic (PGx) studies have been limited by small sample sizes, lack of consensus regarding relevant genetic variants, and cross-sectional designs. The current study aimed to investigate the association between PGx variants and long-term clinical outcomes in 691 patients of European ancestry with SSD. Using evidence from the literature on candidate genes involved in antipsychotic pharmacodynamics, we created a polygenic risk score (PRS) to investigate its association with clinical outcomes. We also created PRS using core variants of psychotropic drug metabolism enzymes CYP2D6 and CYP2C19. Furthermore, the CYP2D6 and CYP2C19 functional activity scores were calculated to determine the relationship between metabolism and clinical outcomes. We found no association for PGx PRSs and clinical outcomes; however, an association was found with CYP2D6 activity scores by the traditional method. Higher CYP2D6 metabolism was associated with high positive and high cognitive impairment groups relative to low symptom severity groups. These findings highlight the need to test PGx efficacy with different symptom domains. More evidence is needed before pharmacogenetic variation can contribute to personalized treatment plans.
- 4 September 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (9) , 1354
Open AccessPharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
Schizophrenia spectrum disorders (SSD) are complex mental disorders, and while treatment with antipsychotics is important, many patients do not respond or develop serious side effects. Genetic variation has been shown to play a considerable role in determining an individual’s response to antipsychotic medication. However, previous pharmacogenetic (PGx) studies have been limited by small sample sizes, lack of consensus regarding relevant genetic variants, and cross-sectional designs. The current study aimed to investigate the association between PGx variants and long-term clinical outcomes in 691 patients of European ancestry with SSD. Using evidence from the literature on candidate genes involved in antipsychotic pharmacodynamics, we created a polygenic risk score (PRS) to investigate its association with clinical outcomes. We also created PRS using core variants of psychotropic drug metabolism enzymes CYP2D6 and CYP2C19. Furthermore, the CYP2D6 and CYP2C19 functional activity scores were calculated to determine the relationship between metabolism and clinical outcomes. We found no association for PGx PRSs and clinical outcomes; however, an association was found with CYP2D6 activity scores by the traditional method. Higher CYP2D6 metabolism was associated with high positive and high cognitive impairment groups relative to low symptom severity groups. These findings highlight the need to test PGx efficacy with different symptom domains. More evidence is needed before pharmacogenetic variation can contribute to personalized treatment plans.
- Open Access
Genetic meta-analysis of obsessive-compulsive disorder and self-report compulsive symptoms
We investigated whether obsessive compulsive (OC) symptoms from a population-based sample could be analyzed to detect genetic variants influencing OCD. We performed a GWAS on the obsession (rumination and impulsions) and compulsion (checking, washing, and ordering/precision) subscales of an abbreviated version of the Padua Inventory (N=8267 with genome-wide genotyping and phenotyping). The compulsion subscale showed a substantial and significant positive genetic correlation with an OCD case-control GWAS (r G =0.61, p=0.017) previously published by the Psychiatric Genomics Consortium (PGC-OCD). The obsession subscale and the total Padua score showed no significant genetic correlations (r G =–0.02 and r G =0.42, respectively). A meta-analysis of the compulsive symptoms GWAS with the PGC-OCD revealed no genome-wide significant SNPs (combined N=17992, indicating that the power is still low for individual SNP effects). A gene-based association analysis, however, yielded two novel genes ( WDR7 and ADCK1 ). The top 250 genes in the gene-based test also showed significant increase in enrichment for psychiatric and brain-expressed genes. S-Predixcan testing showed that for genes expressed in hippocampus, amygdala, and caudate nucleus significance increased in the meta-analysis with compulsive symptoms compared to the original PGC-OCD GWAS. Thus, inclusion of dimensional symptom data in genome-wide association on clinical case-control GWAS of OCD may be useful to find genes for OCD if the data are based on quantitative indices of compulsive behavior. SNP-level power increases were limited, but aggregate, gene-level analyses showed increased enrichment for brain-expressed genes related to psychiatric disorders, and increased association with gene-expression in brain tissues with known emotional, reward processing, memory, and fear-formation functions.
Open AccessGenetic meta-analysis of obsessive-compulsive disorder and self-report compulsive symptoms
We investigated whether obsessive compulsive (OC) symptoms from a population-based sample could be analyzed to detect genetic variants influencing OCD. We performed a GWAS on the obsession (rumination and impulsions) and compulsion (checking, washing, and ordering/precision) subscales of an abbreviated version of the Padua Inventory (N=8267 with genome-wide genotyping and phenotyping). The compulsion subscale showed a substantial and significant positive genetic correlation with an OCD case-control GWAS (r G =0.61, p=0.017) previously published by the Psychiatric Genomics Consortium (PGC-OCD). The obsession subscale and the total Padua score showed no significant genetic correlations (r G =–0.02 and r G =0.42, respectively). A meta-analysis of the compulsive symptoms GWAS with the PGC-OCD revealed no genome-wide significant SNPs (combined N=17992, indicating that the power is still low for individual SNP effects). A gene-based association analysis, however, yielded two novel genes ( WDR7 and ADCK1 ). The top 250 genes in the gene-based test also showed significant increase in enrichment for psychiatric and brain-expressed genes. S-Predixcan testing showed that for genes expressed in hippocampus, amygdala, and caudate nucleus significance increased in the meta-analysis with compulsive symptoms compared to the original PGC-OCD GWAS. Thus, inclusion of dimensional symptom data in genome-wide association on clinical case-control GWAS of OCD may be useful to find genes for OCD if the data are based on quantitative indices of compulsive behavior. SNP-level power increases were limited, but aggregate, gene-level analyses showed increased enrichment for brain-expressed genes related to psychiatric disorders, and increased association with gene-expression in brain tissues with known emotional, reward processing, memory, and fear-formation functions.
- Open Access
- 14 February 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-10
Design and methods of the ‘monitoring outcomes of psychiatric pharmacotherapy’ (MOPHAR) monitoring program – a study protocol
At many outpatient departments for psychiatry worldwide, standardized monitoring of the safety of prescribed psychotropic drugs is not routinely performed in daily clinical practice. Therefore it is unclear to which extent the drugs used by psychiatric outpatients are prescribed effectively and safely. These issues warrant structured monitoring of medication use, (pre-existing) co-morbidities, effectiveness and side effects during psychiatric outpatient treatment. Improvement of monitoring practices provides an opportunity to ensure that somatic complications and adverse drug effects are detected and dealt with in a timely manner. Structural support for data collection and follow-up tests seems essential for improvement of monitoring practices in psychiatric outpatients. The implementation of a structured somatic monitoring program as part of routine clinical practice, as we describe in this study protocol, may be a solution. In order to address these issues, we developed the innovative program ‘Monitoring Outcomes of Psychiatric Pharmacotherapy (MOPHAR)’. MOPHAR is an infrastructure for implementation of standardized routine outcome monitoring (ROM; including standardized monitoring of treatment effect), monitoring of adverse psychotropic medication effects in psychiatric outpatients, encompassing both somatic adverse effects (e.g. metabolic disturbances) and subjective adverse effects (e.g. sedation or sexual side effects) and medication reconciliation. In the MOPHAR monitoring program, a nurse performs general and psychotropic drug-specific somatic screenings and provides the treating mental health care providers with more and better information on somatic monitoring for treatment decisions. Given our experience regarding implementation of the MOPHAR program, we expect that the MOPHAR program is feasible and beneficial for patients in any MHS organisation. This paper describes the objectives, target population, setting and the composition and roles of the treatment team. It also indicates what measurements are performed at which time points during outpatient treatment in the MOPHAR monitoring program, as well as the research aspects of this project. MOPHAR research has been prospectively registered with the Netherlands Trial Register on 19th of November 2014. ( NL4779 ).
- 14 February 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-10
Open AccessDesign and methods of the ‘monitoring outcomes of psychiatric pharmacotherapy’ (MOPHAR) monitoring program – a study protocol
At many outpatient departments for psychiatry worldwide, standardized monitoring of the safety of prescribed psychotropic drugs is not routinely performed in daily clinical practice. Therefore it is unclear to which extent the drugs used by psychiatric outpatients are prescribed effectively and safely. These issues warrant structured monitoring of medication use, (pre-existing) co-morbidities, effectiveness and side effects during psychiatric outpatient treatment. Improvement of monitoring practices provides an opportunity to ensure that somatic complications and adverse drug effects are detected and dealt with in a timely manner. Structural support for data collection and follow-up tests seems essential for improvement of monitoring practices in psychiatric outpatients. The implementation of a structured somatic monitoring program as part of routine clinical practice, as we describe in this study protocol, may be a solution. In order to address these issues, we developed the innovative program ‘Monitoring Outcomes of Psychiatric Pharmacotherapy (MOPHAR)’. MOPHAR is an infrastructure for implementation of standardized routine outcome monitoring (ROM; including standardized monitoring of treatment effect), monitoring of adverse psychotropic medication effects in psychiatric outpatients, encompassing both somatic adverse effects (e.g. metabolic disturbances) and subjective adverse effects (e.g. sedation or sexual side effects) and medication reconciliation. In the MOPHAR monitoring program, a nurse performs general and psychotropic drug-specific somatic screenings and provides the treating mental health care providers with more and better information on somatic monitoring for treatment decisions. Given our experience regarding implementation of the MOPHAR program, we expect that the MOPHAR program is feasible and beneficial for patients in any MHS organisation. This paper describes the objectives, target population, setting and the composition and roles of the treatment team. It also indicates what measurements are performed at which time points during outpatient treatment in the MOPHAR monitoring program, as well as the research aspects of this project. MOPHAR research has been prospectively registered with the Netherlands Trial Register on 19th of November 2014. ( NL4779 ).